{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:15:19Z","timestamp":1783361719685,"version":"3.54.6"},"reference-count":11,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2022R1A2C1010536"],"award-info":[{"award-number":["NRF-2022R1A2C1010536"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100031738","name":"Korea Medical Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002597","name":"Kyung Hee University","doi-asserted-by":"publisher","award":["KHU-20241076"],"award-info":[{"award-number":["KHU-20241076"]}],"id":[{"id":"10.13039\/501100002597","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized breast cancer treatment, necessitating standardized HER2 testing. However, current immunochemistry-based HER2 assessment faces challenges due to subjectivity and variability among observers, prompting the guidance of artificial intelligence (AI). We evaluated AI\u2019s efficacy in HER2 status assessment and treatment response prediction, especially focusing on complete and intense circumferential HER2-positive (3+) tumor cells. An AI-powered HER2 analyzer (Lunit SCOPE HER2, Lunit Inc., Seoul, South Korea) and three pathologists independently assessed HER2 3\u2009+\u2009tumor cell proportions from whole-slide images of 191 breast cancer cases from Kyung Hee University Hospital. Logistic regression and receiver operating characteristic (ROC) curves determined predictive accuracy. AI-detected 3\u2009+\u2009tumor cell proportions strongly correlated with fluorescent in situ hybridization (FISH) positivity (area under ROC curve [AUC]: 0.783) and pathological complete response (pCR) rates (odds ratio [OR]: 1.003\u20131.052), outperforming pathologists\u2019 assessments. Combining AI improved prediction accuracy of pathologists, with an AUC increased from 0.712\u20130.813 to 0.790\u20130.821 for predicting FISH positivity and median OR increased from 0.996\u20131.061 to 1.003\u20131.055 for predicting pCR. Overall, this preliminary study suggests that AI could enhance HER2 status determination and treatment response prediction, complementing traditional pathological evaluation of HER2 immunohistochemistry.<\/jats:p>","DOI":"10.1371\/journal.pone.0352979","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:27:43Z","timestamp":1783358863000},"page":"e0352979","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Artificial intelligence-detected HER2 strong-positive tumor proportion predicts FISH positivity and treatment response in breast cancer"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1605-2708","authenticated-orcid":true,"given":"Seung Geun","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Ick","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7877-5053","authenticated-orcid":true,"given":"Taeyong","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2626-3052","authenticated-orcid":true,"given":"Sangwon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonkyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisoo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukjun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donggeun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Kyung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyong","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-4282","authenticated-orcid":true,"given":"Minsun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Woon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"20","key":"pone.0352979.ref001","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"AC Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0352979.ref002","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1309\/AJCPT41TCBUEVDQC","article-title":"Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens","volume":"144","author":"D Furrer","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"pone.0352979.ref003","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.modpat.2022.100054","article-title":"The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer","volume":"36","author":"S Wu","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"pone.0352979.ref004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"S Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0352979.ref005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","article-title":"Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)","volume":"42","author":"G Curigliano","year":"2024","journal-title":"JCO"},{"issue":"1","key":"pone.0352979.ref006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13058-024-01784-y","article-title":"Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases","volume":"26","author":"M Jung","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"5","key":"pone.0352979.ref007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"KN Ogston","year":"2003","journal-title":"Breast"},{"key":"pone.0352979.ref008","doi-asserted-by":"crossref","first-page":"6684629","DOI":"10.1155\/2021\/6684629","article-title":"HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer","volume":"2021","author":"TJ Lillemoe","year":"2021","journal-title":"Int J Breast Cancer"},{"issue":"1","key":"pone.0352979.ref009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-019-05295-9","article-title":"Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy","volume":"177","author":"M Krystel-Whittemore","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"pone.0352979.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2021.05.004","article-title":"Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression\/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review Study","volume":"22","author":"R Memon","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"pone.0352979.ref011","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.prp.2016.02.007","article-title":"The relation between percentage of immunostained cells and amplification status in breast cancers with equivocal result for Her2 immunohistochemistry","volume":"212","author":"O Onguru","year":"2016","journal-title":"Pathol Res Pract"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:27:45Z","timestamp":1783358865000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352979"}},"subtitle":[],"editor":[{"given":"Sun Hee","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":11,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352979","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}